The effects of ischemia on metabolism and reperfusion arrhythmias. 1983

S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse

In attempts to determine the mechanism(s) underlying reflow rhythm disturbances, we have studied the relationship between extent of coronary flow impairment and incidence of reperfusion arrhythmias. In isolated guinea pig hearts perfused with pyruvate (10 mmol/l) and glucose (0.5 mmol/l), coronary flow was reduced to different extents (18, 11, 6, 1, and 0.5%). Following 10 minutes of ischemia, reflow arrhythmias were quantitated with computer-aided statistical determination of rate-independent variations in beat intervals. The results (19 +/- 1, 13 +/- 5, 22 +/- 4, 8 +/- 3 and 6 +/- 1, n = 6, Rhythm Disturbance Units respectively) revealed that rhythm disturbances were more serious after less severe ischemia than after more severe ischemia. To investigate this "paradoxical" observation, we compared the metabolic changes during ischemia and the severity of subsequent reflow arrhythmias. Electrical instability during reperfusion was not related to accumulation of lactate, increase in cyclic AMP or decline in energy status. These were at a maximum in the severely ischemic myocardium. The reduced incidence of arrhythmias following severe (1% and 0.5% flow) as opposed to moderate ischemia, however, may have been associated with a major increase in glycogenolysis (from 1.2 to 7.4 and 7.6 mumol glucose equivalents/min per g dry weight).

UI MeSH Term Description Entries
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011773 Pyruvates Derivatives of PYRUVIC ACID, including its salts and esters.
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006003 Glycogen
D006019 Glycolysis A metabolic process that converts GLUCOSE into two molecules of PYRUVIC ACID through a series of enzymatic reactions. Energy generated by this process is conserved in two molecules of ATP. Glycolysis is the universal catabolic pathway for glucose, free glucose, or glucose derived from complex CARBOHYDRATES, such as GLYCOGEN and STARCH. Embden-Meyerhof Pathway,Embden-Meyerhof-Parnas Pathway,Embden Meyerhof Parnas Pathway,Embden Meyerhof Pathway,Embden-Meyerhof Pathways,Pathway, Embden-Meyerhof,Pathway, Embden-Meyerhof-Parnas,Pathways, Embden-Meyerhof

Related Publications

S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
January 2000, European journal of pharmacology,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
January 1992, The Chinese journal of physiology,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
April 1991, Proceedings of the National Science Council, Republic of China. Part B, Life sciences,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
March 1991, Cardiovascular drugs and therapy,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
June 1995, The American journal of physiology,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
January 2015, Iranian journal of basic medical sciences,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
January 1985, Arzneimittel-Forschung,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
January 1990, Journal of cardiovascular pharmacology,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
April 2002, Pharmacological research,
S C Dennis, and D M Yellon, and F Frasch, and G J Anderson, and D J Hearse
June 1991, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!